Recent strides in anti-cancer therapeutics have improved longevity and led to a growing
population of cancer survivors, who are increasingly likely to die of other causes. Treatment …

Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has
risen to become a prominent clinical challenge. This has led to the growth of the burgeoning …

Background: Doxorubicin is an effective chemotherapy drug for treating various types of
cancer. However, lethal cardiotoxicity severely limits its clinical use. Recent evidence has …

Heart failure is a clinical syndrome where cardiac output is not sufficient to sustain adequate
perfusion and normal bodily functions, initially during exercise and in more severe forms …

We review some of the important discoveries and advances made in basic and translational
cardiac research in 2020. For example, in the field of myocardial infarction (MI), new aspects …

Thanks to the fantastic progress in cancer therapy options, there is a growing population of
cancer survivors. This success has resulted in a need to focus much effort into improving the …

Myocardial protection against ischemia/reperfusion injury (IRI) is mediated by various
ligands, activating different cellular signaling cascades. These include classical cytosolic …

Cardiac fibrosis is associated with activation of cardiac fibroblasts (CFs), a pathological,
phenotypic transition that is widely believed to be irreversible in the late stages of disease …

Microcirculation is pervasive and orchestrates a profound regulatory cross-talk with the
surrounding tissue and organs. Similarly, it is one of the earliest biological systems targeted …

Aims There is a lack of therapies able to prevent anthracycline cardiotoxicity (AC). Remote
ischaemic conditioning (RIC) has shown beneficial effects in preclinical models of AC …